radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses – preclinical evidence and ongoing clinical applications
Clicks: 344
ID: 258419
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
344 views
53 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #50 of 644 articles by views in sudebno-meditsinskaia ekspertiza
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Radiotherapy (RT) primarily aims to locally destroy the tumor via the induction of DNA damage in the tumor cells. However, so called abscopal, namely systemic and immune mediated effects of RT move over more and more in the focus of scientists and clinicians since combinations of local irradiation with immune therapy have been demonstrated to induce anti-tumor immunity. We here summarize changes of the phenotype and microenvironment of tumor cells after exposure to irradiation, chemotherapeutic agents and immune modulating agents rendering the tumor more immunogenic. The impact of therapy-modified tumor cells and damage associated molecular patterns (DAMPs) on local and systemic control of the primary tumor, recurrent tumors and metastases will be outlined. Finally, clinical studies affirming the bench-side findings of interactions and synergies of radiation therapy and immunotherapy will be discussed. Focus is set on combination of radio(chemo)therapy (RCT) with immune checkpoint inhibitors, growth factor inhibitors and chimeric antigen receptor (CAR) T-cell therapy. Well deliberated combination of RCT with selected immune therapies and growth factor inhibitors bear the great potential to further improve anti-cancer therapies.
| Reference Key |
ederer2015frontiersradio-immunotherapy-induced
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Anja eDerer;Lisa eDeloch;Yvonne eRubner;Rainer eFietkau;Benjamin eFrey;Udo S Gaipl |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2015 |
| DOI |
10.3389/fimmu.2015.00505
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.